Delcath Systems posted Q2 revenue of $29.1 million, up 20.25% from a year earlier, led by HEPZATO KIT revenue of $27.1 million.
Net income was $2.7 million, unchanged from the prior-year quarter, while gross margin widened 4 percentage points to 90%.
Non-GAAP adjusted EBITDA fell 22.45% to $7.6 million; cash and investments totaled $95.9 million at June 30, with no debt.
Active treatment centers rose to 31, with HEPZATO volume up about 30% year over year; the first patient was dosed in a global Phase 2 breast cancer trial.
Delcath raised 2026 revenue guidance to $104 million-$108 million, projecting at least 28% growth in HEPZATO KIT volume versus 2025.
DCTH•
